<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879358</url>
  </required_header>
  <id_info>
    <org_study_id>SORT OUT VII</org_study_id>
    <secondary_id>OUH</secondary_id>
    <nct_id>NCT01879358</nct_id>
  </id_info>
  <brief_title>Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent</brief_title>
  <acronym>SORT OUT VII</acronym>
  <official_title>Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is
      to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the
      biolimus-eluting NOBORI stent in a population-based setting, using registry detection of
      clinically driven events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SORT OUT VII is a randomized, multicenter, all-comer, two-arm, non-inferiority trial
      comparing the sirolimus eluting ORSIRO stent to the biolimus-eluting NOBORI stent in treating
      atherosclerotic coronary artery lesions.

      Primary Endpoint:

      Target lesion failure within 12 months of stent implantation (combination of cardiac death,
      myocardial infarction (not index procedure related) not related to other than index lesion or
      target lesion revascularization).

      Secondary Endpoints:

      Individual components of the primary end point comprised the secondary end points and stent
      thrombosis rate according to the Academic Research Consortium definition (see protocol for
      further specification of secondary endpoints).

      Clinically driven event detection will be used to avoid study-induced reinterventions. Data
      on mortality, hospital admission, coronary angiography, repeat percutaneous coronary
      intervention, and coronary bypass surgery will be obtained for all randomly allocated
      patients from the following national Danish administrative and healthcare registries: the
      Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry
      of Patients, which maintains records on all hospitalizations in Denmark; and the Danish
      Registry of Causes of Death

      Inclusion criteria:

      at least 18 years old chronic stable coronary artery disease or acute coronary syndromes at
      least one coronary artery lesion with more than 50% diameter stenosis requiring treatment
      with a drug-eluting stent

      Exclusion criteria:

      life expectancy of less than one year allergy to aspirin, clopidogrel, sirolimus, or biolimus
      participation in another randomized trial nability to provide written informed consent
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death, myocardial infarction or target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion failure within 12 months of stent implantation (combination of cardiac death, myocardial infarction (not index procedure related) not related to other than index lesion or target lesion revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death, myocardial infarction, target lesion revascularization, target vessel revascularization, all cause mortality, stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac mortality Myocardial infarction Target lesion revascularization Target vessel revascularization All cause mortality Stent thrombosis rate according to the Academic Research Consortium definition Secondary endpoints will be assessed after 1 year, 2 years, 3 years, 4 years and 5 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2314</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>ORSIRO stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ORSIRO stent group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOBORI stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NOBORI stent group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting stent</intervention_name>
    <arm_group_label>ORSIRO stent</arm_group_label>
    <arm_group_label>NOBORI stent</arm_group_label>
    <other_name>ORSIRO sirolimus-eluting stent</other_name>
    <other_name>NOBORI biolimus-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or over with chronic stable coronary artery disease or acute
             coronary syndromes, and at least one coronary artery lesion with more than 50%
             diameter stenosis, requiring treatment with a drug-eluting stent. There are no
             restrictions on number of treated lesions, number of treated vessels, or lesion
             length.

        Exclusion Criteria:

          -  Exclusion criteria are life expectancy of less than one year; an allergy to aspirin,
             clopidogrel, ticagrelor, prasugral, sirolimus, or biolimus; participation in another
             randomized trial; or inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens F Lassen, MD DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22308301</url>
    <description>SORT OUT IV with same clinically event driven methodology</description>
  </link>
  <reference>
    <citation>Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A, Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Bøtker HE, Ravkilde J, Sanchez R, Aarøe J, Madsen M, Sørensen HT, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012 Mar 13;125(10):1246-55. doi: 10.1161/CIRCULATIONAHA.111.063644. Epub 2012 Feb 3. Erratum in: Circulation. 2013 Sep 3;128(10):e158. Noergaard, Bjarne Linde [corrected to Norgaard, Bjarne Linde].</citation>
    <PMID>22308301</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lisette Okkels Jensen</investigator_full_name>
    <investigator_title>MD DMSci PhD</investigator_title>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

